Additionally, the presence of a mutation in the isocitrate dehydrogenase (IDH) genes—which has been identified as a positive prognostic marker—is linked to dedifferentiated low-grade gliomas which have a distinctly different clinical behavior compared to IDH wild-type (WT) GBM [8]. This evidence concerns the gene IDH1 and glioma.